{"protocolSection":{"identificationModule":{"nctId":"NCT03001882","orgStudyIdInfo":{"id":"CA209-592"},"secondaryIdInfos":[{"id":"2018-000462-11","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)","acronym":"CheckMate 592"},"statusModule":{"statusVerifiedDate":"2024-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-03-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2022-02-17","type":"ACTUAL"},"completionDateStruct":{"date":"2023-04-24","type":"ACTUAL"},"studyFirstSubmitDate":"2016-12-21","studyFirstSubmitQcDate":"2016-12-22","studyFirstPostDateStruct":{"date":"2016-12-23","type":"ESTIMATED"},"resultsFirstSubmitDate":"2023-02-02","resultsFirstSubmitQcDate":"2023-05-09","resultsFirstPostDateStruct":{"date":"2023-06-06","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-04-22","lastUpdatePostDateStruct":{"date":"2024-05-20","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"},"collaborators":[{"name":"Yale University","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to explore the possible links between participant characteristics and their cancer, with how effective the combination of nivolumab with ipilimumab is, in participants with Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":230,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Combination therapy","type":"EXPERIMENTAL","description":"Nivolumab + Ipilimumab","interventionNames":["Biological: Nivolumab","Biological: Ipilimumab"]}],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","description":"Specified dose on specified days","armGroupLabels":["Combination therapy"],"otherNames":["Opdivo","BMS-936558"]},{"type":"BIOLOGICAL","name":"Ipilimumab","description":"Specified dose on specified days","armGroupLabels":["Combination therapy"],"otherNames":["Yervoy","BMS-734016"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB)","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nBlood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","timeFrame":"From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 58 months)"},{"measure":"Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (Blood TMB Cut-point = 21-mutations/MB)","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nBlood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","timeFrame":"From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 58 months)"},{"measure":"Objective Response Rate (ORR) Per Investigator by Tissue TMB Within PD-L1 Subgroup (Tissue TMB Cut-point = 10-mutations/MB)","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nTissue tumor mutational burden (tTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in tumor tissue samples.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","timeFrame":"From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 58 months)"}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR) for All Treated Participants by Investigator Per RECIST 1.1","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPartial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","timeFrame":"From first dose until the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy, whichever occurs first (Up to approximately 67 months)"},{"measure":"Disease Control Rate (DCR) for Part 1","description":"Disease control rate (DCR) is the percent of treated participants with a best overall response of a complete response (CR), partial response (PR), or stable disease (SD), assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, using the baseline sum diameters as reference. CR is disappearance of all target lesions and a reduction in short axis to \\<10 mm of any pathological lymph nodes (target or non-target). SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking smallest sum diameters as reference. PD is at least a 20% increase in the sum of diameters of target lesions, taking the smallest sum as reference. The sum must also demonstrate an absolute increase of at least 5 mm. (one or more new lesions is also considered progression). CR+PR, confidence interval based on the Clopper and Pearson method.","timeFrame":"From first dose until the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy, whichever occurs first (Up to approximately 67 months)"},{"measure":"Duration of Response (DOR) for Part 1","description":"DOR is the time between first confirmed response (Complete/Partial Response) and first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who don't progress or die are censored on the date of their last evaluable tumor assessment. Participants who started subsequent anti-cancer therapy without prior reported progression were censored at the last evaluable tumor assessment prior to or on the date of subsequent anti-cancer therapy.\n\nPR is at least 30% decrease in the sum of diameters of target lesions, using baseline sum diameters as reference. CR is disappearance of all target lesions and reduction in short axis to \\<10 mm of any pathological lymph nodes (target or non-target). Progressive Disease (PD) is at least 20% increase in the sum of diameters of target lesions, taking the smallest sum as reference. The sum must also show an overall increase of \\> 5 mm. (one or more new lesions is also progression). Median computed using Kaplan-Meier method.","timeFrame":"From first dose to the date of the first documented tumor progression or death due to any cause (Up to approximately 67 months)"},{"measure":"Time to Response (TTR) for Part 1","description":"TTR is the time taken from first dosing date to the time the criteria for Complete Response (CR)/Partial Response (PR) are first met.\n\nPartial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm.","timeFrame":"From first dose to the time the criteria for Complete Response/Partial Response are first met (Up to approximately 67 months)"},{"measure":"Progression Free Survival (PFS)","description":"PFS is defined as the time from first dosing date to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause.\n\nParticipants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last evaluable tumor assessment prior to or on the date of initiation of subsequent anti-cancer therapy.\n\nProgressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking the smallest sum on study as reference. The sum must also show an overall increase of \\> 5 mm. (one or more new lesions is also progression).\n\nMedian calculated using Kaplan-Meier estimates.","timeFrame":"From first dose to the date of the first documented tumor progression or death due to any causes (Assessed up to approximately 67 months)"},{"measure":"Overall Survival (OS)","description":"OS is defined as the time from first dosing date to the date of death. If a participant didn't die, OS will be censored on the last date the participant was known to be alive.\n\nMedian based on Kaplan-Meier estimates.","timeFrame":"From first dose to the date of death (Assessed up to approximately 67 months)"},{"measure":"Number of Participants With Adverse Events (AEs) for Study Part 2","description":"An Adverse Event (AE) is any new untoward medical occurrence or worsening preexisting medical condition in a treated participant and that does not necessarily have a causal relationship with treatment.\n\nAn AE can be any unfavorable, unintended sign, symptom, or disease temporally associated with the use of treatment, whether or not related to the treatment.","timeFrame":"From first dose to 30 days after last dosing date (assessed up to approximately 27 months)"},{"measure":"Number of Participants With Serious Adverse Events (SAEs) for Study Part 2","description":"A Serious Adverse Event (SAE) results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), or requires inpatient hospitalization or causes prolongation of existing hospitalization.","timeFrame":"From first dose to 30 days after last dosing date (assessed up to approximately 27 months)"},{"measure":"Number of Participants With Select Adverse Events (AEs) for Study Part 2","description":"An Adverse Event (AE) is any new untoward medical occurrence or worsening preexisting medical condition in a treated participant and that does not necessarily have a causal relationship with treatment.\n\nAn AE can be any unfavorable, unintended sign, symptom, or disease temporally associated with the use of treatment, whether or not related to the treatment.","timeFrame":"From first dose to 30 days after last dosing date (up to approximately 27 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed, stage IV or recurrent non-small cell lung cancer with no prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease\n* Measurable disease by CT or MRI\n* Must have full activity or, if limited, must be able to walk and carry out light activities such as light house work or office work\n\nExclusion Criteria:\n\n* Participants with untreated central nervous system metastases\n* Participants with active, known or suspected autoimmune disease\n* Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors)\n\nOther protocol defined inclusion/exclusion criteria apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Local Institution - 0006","city":"Springdale","state":"Arkansas","zip":"72762","country":"United States","geoPoint":{"lat":36.18674,"lon":-94.12881}},{"facility":"Local Institution - 0001","city":"New Haven","state":"Connecticut","zip":"06520","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Local Institution - 0005","city":"Jacksonville","state":"Florida","zip":"32256","country":"United States","geoPoint":{"lat":30.33218,"lon":-81.65565}},{"facility":"Local Institution - 0009","city":"Atlanta","state":"Georgia","zip":"30322","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Local Institution - 0003","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Local Institution - 0038","city":"The Bronx","state":"New York","zip":"10461","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Local Institution - 0002","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Local Institution - 0008","city":"Cleveland","state":"Ohio","zip":"44195","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Local Institution - 0007","city":"Greenville","state":"South Carolina","zip":"29607","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Local Institution - 0004","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Local Institution - 0017","city":"La Louvière","state":"Hainaut","zip":"7100","country":"Belgium","geoPoint":{"lat":50.48657,"lon":4.18785}},{"facility":"Local Institution - 0018","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Local Institution - 0028","city":"Ghent","zip":"9000","country":"Belgium","geoPoint":{"lat":51.05,"lon":3.71667}},{"facility":"Local Institution - 0027","city":"Liège","zip":"4000","country":"Belgium","geoPoint":{"lat":50.63373,"lon":5.56749}},{"facility":"Local Institution - 0016","city":"Sint-Niklaas","zip":"9100","country":"Belgium","geoPoint":{"lat":51.16509,"lon":4.1437}},{"facility":"Local Institution - 0036","city":"Paris","zip":"75248","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Local Institution - 0033","city":"Pierre-Bénite","zip":"69495","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"facility":"Local Institution - 0034","city":"Strasbourg","zip":"67091","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Local Institution - 0039","city":"Toulon","zip":"83000","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"Local Institution - 0015","city":"Essen","zip":"45136","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"Local Institution - 0014","city":"Immenstadt im Allgäu","zip":"87509","country":"Germany","geoPoint":{"lat":47.55996,"lon":10.21394}},{"facility":"Local Institution - 0013","city":"Löwenstein","zip":"74245","country":"Germany","geoPoint":{"lat":49.09558,"lon":9.38}},{"facility":"Local Institution - 0012","city":"Stuttgart","zip":"70174","country":"Germany","geoPoint":{"lat":48.78232,"lon":9.17702}},{"facility":"Local Institution - 0023","city":"Bergamo","zip":"24127","country":"Italy","geoPoint":{"lat":45.69601,"lon":9.66721}},{"facility":"Local Institution - 0025","city":"Catania","zip":"95123","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Local Institution - 0026","city":"Parma","zip":"43100","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Local Institution - 0024","city":"Perugia","zip":"06129","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Local Institution - 0021","city":"Amsterdam","zip":"1066 CX","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"facility":"Local Institution - 0022","city":"Nijmegen","zip":"6525 GA","country":"Netherlands","geoPoint":{"lat":51.8425,"lon":5.85278}},{"facility":"Local Institution - 0011","city":"Cluj-Napoca","state":"Cluj","zip":"400015","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"Local Institution - 0010","city":"Craiova","zip":"200542","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"Local Institution - 0031","city":"Barcelona","zip":"08908","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Local Institution - 0029","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0030","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Local Institution - 0032","city":"Seville","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}}]},"referencesModule":{"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"http://www.BMSStudyConnect.com"}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"In Part 1, upon determination of PD-L1 status (cut-off of 1%), 2 cohorts were defined: PD-L1 positive and negative.\n\nIn Part 2, a separate group of participants were treated regardless of their PD-L1 status.","groups":[{"id":"FG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"FG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"FG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"FG003","title":"PART 2: PD-L1 Status Independent","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"170"}]},{"type":"COMPLETED","comment":"Continuing in treatment period","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"31"},{"groupId":"FG001","numSubjects":"28"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"170"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Participant withdrew consent","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"5"}]},{"type":"Other reasons","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"5"}]},{"type":"Administrative reason by sponsor","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}]},{"type":"Participant requested to discontinue study treatment","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]},{"type":"Not reported","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"6"}]},{"type":"Maximum clinical benefit","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"10"}]},{"type":"AE unrelated to study drug","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"11"}]},{"type":"Study Drug Toxicity","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"37"}]},{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"90"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"BG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"BG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"BG003","title":"PART 2: PD-L1 Status Independent","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"170"},{"groupId":"BG004","value":"230"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"76"},{"groupId":"BG004","value":"101"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"94"},{"groupId":"BG004","value":"129"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"54"},{"groupId":"BG004","value":"80"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"116"},{"groupId":"BG004","value":"150"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"6"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"98"},{"groupId":"BG004","value":"148"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"68"},{"groupId":"BG004","value":"76"}]}]}]},{"title":"Race/Ethnicity, Customized","description":"Race","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"164"},{"groupId":"BG004","value":"217"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"11"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (TMB Cut-point = 16 Mutations/MB)","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nBlood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","populationDescription":"All treated PD-L1 and bTMB evaluable Part 1 and 2 participants (Blood TMB Cut-point = 16 mutations/MB). Non-evaluable PD-L1 status means that PD-L1 status could not be determined, thus the Arm population did not meet this criteria. Participants in Part 2: PD-L1(+/-) Status groups were stratified from the PART 2: PD-L1 Status Independent Arm. Not all participants were bTMB evaluable. To be analyzed participants had to be both PD-L1 evaluable and bTMB evaluable.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percent of Participants","timeFrame":"From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 58 months)","groups":[{"id":"OG000","title":"PART 1: PD-L1 + Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG003","title":"PART 2: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"},{"id":"OG004","title":"PART 2: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"62"}]}],"classes":[{"title":"bTMB High (Cut-point = 16-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"33"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30","lowerLimit":"6.7","upperLimit":"65.2"},{"groupId":"OG001","value":"50","lowerLimit":"18.7","upperLimit":"81.3"},{"groupId":"OG003","value":"58.8","lowerLimit":"32.9","upperLimit":"81.6"},{"groupId":"OG004","value":"30.3","lowerLimit":"15.6","upperLimit":"48.7"}]}]},{"title":"bTMB Low (Cut-point = 16-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"7.5","upperLimit":"70.1"},{"groupId":"OG001","value":"33.3","lowerLimit":"4.3","upperLimit":"77.7"},{"groupId":"OG003","value":"31.8","lowerLimit":"13.9","upperLimit":"54.9"},{"groupId":"OG004","value":"24.1","lowerLimit":"10.3","upperLimit":"43.5"}]}]}]},{"type":"PRIMARY","title":"Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) Within PD-L1 Subgroup (Blood TMB Cut-point = 21-mutations/MB)","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nBlood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","populationDescription":"All treated PD-L1 and bTMB evaluable Part 1 and Part 2 participants (Blood TMB Cut-point = 21-mutations/MB). Non-evaluable PD-L1 status means that PD-L1 status could not be determined, thus the Arm population did not meet this criteria. Participants in Part 2: PD-L1(+/-) Status groups were stratified from the PART 2: PD-L1 Status Independent Arm. Not all participants were bTMB evaluable. To be analyzed participants had to be both PD-L1 evaluable and bTMB evaluable.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percent of Participants","timeFrame":"From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 58 months)","groups":[{"id":"OG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG003","title":"PART 2: PD-L1 + Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"},{"id":"OG004","title":"PART 2: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"62"}]}],"classes":[{"title":"bTMB High (Cut-point = 21-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"4.3","upperLimit":"77.7"},{"groupId":"OG001","value":"66.7","lowerLimit":"22.3","upperLimit":"95.7"},{"groupId":"OG003","value":"64.3","lowerLimit":"35.1","upperLimit":"87.2"},{"groupId":"OG004","value":"40.9","lowerLimit":"20.7","upperLimit":"63.6"}]}]},{"title":"bTMB Low (Cut-point = 21-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"40"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"9.1","upperLimit":"61.4"},{"groupId":"OG001","value":"30.0","lowerLimit":"6.7","upperLimit":"65.2"},{"groupId":"OG003","value":"32.0","lowerLimit":"14.9","upperLimit":"53.5"},{"groupId":"OG004","value":"20.0","lowerLimit":"9.1","upperLimit":"35.6"}]}]}]},{"type":"PRIMARY","title":"Objective Response Rate (ORR) Per Investigator by Tissue TMB Within PD-L1 Subgroup (Tissue TMB Cut-point = 10-mutations/MB)","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nTissue tumor mutational burden (tTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in tumor tissue samples.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","populationDescription":"All treated PD-L1 and bTMB evaluable Part 1 and Part 2 participants (Blood TMB Cut-point = 10-mutations/MB). Non-evaluable PD-L1 status means that PD-L1 status could not be determined, thus the Arm population did not meet this criteria. Participants in Part 2: PD-L1(+/-) Status groups were stratified from the PART 2: PD-L1 Status Independent Arm. Not all participants were bTMB evaluable. To be analyzed participants had to be both PD-L1 evaluable and bTMB evaluable.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percent of Participants","timeFrame":"From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 58 months)","groups":[{"id":"OG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG003","title":"PART 2: PD-L1 + Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"},{"id":"OG004","title":"PART 2: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"31"},{"groupId":"OG004","value":"57"}]}],"classes":[{"title":"tTMB High (Cut-point = 10-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"3.2","upperLimit":"65.1"},{"groupId":"OG001","value":"71.4","lowerLimit":"29.0","upperLimit":"96.3"},{"groupId":"OG003","value":"60.0","lowerLimit":"32.3","upperLimit":"83.7"},{"groupId":"OG004","value":"46.7","lowerLimit":"21.3","upperLimit":"73.4"}]}]},{"title":"tTMB Low (Cut-point = 10-mutations","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","lowerLimit":"6.0","upperLimit":"61.0"},{"groupId":"OG001","value":"22.2","lowerLimit":"2.8","upperLimit":"60.0"},{"groupId":"OG003","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG004","value":"21.4","lowerLimit":"10.3","upperLimit":"36.8"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) for All Treated Participants by Investigator Per RECIST 1.1","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPartial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","populationDescription":"All treated Part 1 and Part 2 participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percent of Participants","timeFrame":"From first dose until the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy, whichever occurs first (Up to approximately 67 months)","groups":[{"id":"OG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG003","title":"PART 2: PD-L1 Status Independent","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.0","lowerLimit":"14.2","upperLimit":"48.0"},{"groupId":"OG001","value":"39.3","lowerLimit":"21.5","upperLimit":"59.4"},{"groupId":"OG002","value":"0","lowerLimit":"0.0","upperLimit":"97.5"},{"groupId":"OG003","value":"29.4","lowerLimit":"22.7","upperLimit":"36.9"}]}]}]},{"type":"SECONDARY","title":"Disease Control Rate (DCR) for Part 1","description":"Disease control rate (DCR) is the percent of treated participants with a best overall response of a complete response (CR), partial response (PR), or stable disease (SD), assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, using the baseline sum diameters as reference. CR is disappearance of all target lesions and a reduction in short axis to \\<10 mm of any pathological lymph nodes (target or non-target). SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking smallest sum diameters as reference. PD is at least a 20% increase in the sum of diameters of target lesions, taking the smallest sum as reference. The sum must also demonstrate an absolute increase of at least 5 mm. (one or more new lesions is also considered progression). CR+PR, confidence interval based on the Clopper and Pearson method.","populationDescription":"All treated participants in Part 1. Endpoint pre-specified only for participants treated in Part 1.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percent of Participants","timeFrame":"From first dose until the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy, whichever occurs first (Up to approximately 67 months)","groups":[{"id":"OG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"1"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","lowerLimit":"39.1","upperLimit":"75.5"},{"groupId":"OG001","value":"64.3","lowerLimit":"44.1","upperLimit":"81.4"},{"groupId":"OG002","value":"100.0","lowerLimit":"2.5","upperLimit":"100.0"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) for Part 1","description":"DOR is the time between first confirmed response (Complete/Partial Response) and first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who don't progress or die are censored on the date of their last evaluable tumor assessment. Participants who started subsequent anti-cancer therapy without prior reported progression were censored at the last evaluable tumor assessment prior to or on the date of subsequent anti-cancer therapy.\n\nPR is at least 30% decrease in the sum of diameters of target lesions, using baseline sum diameters as reference. CR is disappearance of all target lesions and reduction in short axis to \\<10 mm of any pathological lymph nodes (target or non-target). Progressive Disease (PD) is at least 20% increase in the sum of diameters of target lesions, taking the smallest sum as reference. The sum must also show an overall increase of \\> 5 mm. (one or more new lesions is also progression). Median computed using Kaplan-Meier method.","populationDescription":"All treated participants in Part 1 who had complete or partial response. Endpoint pre-specified only for participants treated in Part 1.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"From first dose to the date of the first documented tumor progression or death due to any cause (Up to approximately 67 months)","groups":[{"id":"OG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.56","lowerLimit":"1.9","upperLimit":"61.7"},{"groupId":"OG001","value":"29.57","lowerLimit":"2.8","upperLimit":"48.9"}]}]}]},{"type":"SECONDARY","title":"Time to Response (TTR) for Part 1","description":"TTR is the time taken from first dosing date to the time the criteria for Complete Response (CR)/Partial Response (PR) are first met.\n\nPartial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm.","populationDescription":"All treated participants in Part 1 who had complete or partial response. Endpoint pre-specified only for participants treated in Part 1.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"From first dose to the time the criteria for Complete Response/Partial Response are first met (Up to approximately 67 months)","groups":[{"id":"OG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"0"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","lowerLimit":"1.6","upperLimit":"3.7"},{"groupId":"OG001","value":"5.26","lowerLimit":"1.7","upperLimit":"18.5"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS is defined as the time from first dosing date to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause.\n\nParticipants who neither progress nor die will be censored on the date of their last evaluable tumor assessment. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be censored at the last evaluable tumor assessment prior to or on the date of initiation of subsequent anti-cancer therapy.\n\nProgressive Disease (PD) is at least a 20% increase in the sum of diameters of target lesions, taking the smallest sum on study as reference. The sum must also show an overall increase of \\> 5 mm. (one or more new lesions is also progression).\n\nMedian calculated using Kaplan-Meier estimates.","populationDescription":"All treated Part 1 and Part 2 participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first dose to the date of the first documented tumor progression or death due to any causes (Assessed up to approximately 67 months)","groups":[{"id":"OG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG003","title":"PART 2: PD-L1 Status Independent","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.71","lowerLimit":"1.97","upperLimit":"8.90"},{"groupId":"OG001","value":"4.30","lowerLimit":"1.84","upperLimit":"13.60"},{"groupId":"OG002","value":"3.61","lowerLimit":"NA","upperLimit":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG003","value":"6.28","lowerLimit":"5.09","upperLimit":"7.56"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from first dosing date to the date of death. If a participant didn't die, OS will be censored on the last date the participant was known to be alive.\n\nMedian based on Kaplan-Meier estimates.","populationDescription":"All treated Part 1 and Part 2 participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From first dose to the date of death (Assessed up to approximately 67 months)","groups":[{"id":"OG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG003","title":"PART 2: PD-L1 Status Independent","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.63","lowerLimit":"4.47","upperLimit":"20.57"},{"groupId":"OG001","value":"22.29","lowerLimit":"11.56","upperLimit":"25.23"},{"groupId":"OG002","value":"9.23","lowerLimit":"NA","upperLimit":"NA","comment":"Insufficient number of participants with events"},{"groupId":"OG003","value":"14.78","lowerLimit":"11.99","upperLimit":"20.60"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) for Study Part 2","description":"An Adverse Event (AE) is any new untoward medical occurrence or worsening preexisting medical condition in a treated participant and that does not necessarily have a causal relationship with treatment.\n\nAn AE can be any unfavorable, unintended sign, symptom, or disease temporally associated with the use of treatment, whether or not related to the treatment.","populationDescription":"All treated Part 2 participants. Endpoint pre-specified only for participants treated in Part 2.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days after last dosing date (assessed up to approximately 27 months)","groups":[{"id":"OG000","title":"PART 2: PD-L1 Status Independent","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"169"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAEs) for Study Part 2","description":"A Serious Adverse Event (SAE) results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), or requires inpatient hospitalization or causes prolongation of existing hospitalization.","populationDescription":"All treated Part 2 participants. Endpoint pre-specified only for participants treated in Part 2.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days after last dosing date (assessed up to approximately 27 months)","groups":[{"id":"OG000","title":"PART 2: PD-L1 Status Independent","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"102"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Select Adverse Events (AEs) for Study Part 2","description":"An Adverse Event (AE) is any new untoward medical occurrence or worsening preexisting medical condition in a treated participant and that does not necessarily have a causal relationship with treatment.\n\nAn AE can be any unfavorable, unintended sign, symptom, or disease temporally associated with the use of treatment, whether or not related to the treatment.","populationDescription":"All treated Part 2 participants. Endpoint pre-specified only for participants treated in Part 2.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 30 days after last dosing date (up to approximately 27 months)","groups":[{"id":"OG000","title":"PART 2: PD-L1 Status Independent","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"}]}],"classes":[{"title":"Gastrointestinal Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"68"}]}]},{"title":"Hepatic Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}]},{"title":"Pulmonary Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]},{"title":"Renal Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]},{"title":"Skin Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"73"}]}]},{"title":"Hypersensitivity/Infusion Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}]}]},{"type":"POST_HOC","title":"Extended Collection of Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) (TMB Cut-point = 16 Mutations/MB)","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nBlood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","populationDescription":"All treated PD-L1 and bTMB evaluable Part 1 and 2 participants (Blood TMB Cut-point = 16 mutations/MB). Non-evaluable PD-L1 status means that PD-L1 status could not be determined, thus the Arm population did not meet this criteria. Not all participants were bTMB evaluable. To be analyzed participants had to be both PD-L1 evaluable and bTMB evaluable.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percent of Participants","timeFrame":"From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 67 months)","groups":[{"id":"OG000","title":"PART 1","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 2","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"131"}]}],"classes":[{"title":"bTMB High (Cut-point = 16-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.0","lowerLimit":"19.1","upperLimit":"63.9"},{"groupId":"OG002","value":"34.4","lowerLimit":"22.9","upperLimit":"47.3"}]}]},{"title":"bTMB Low (Cut-point = 16-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"7.3","upperLimit":"52.4"},{"groupId":"OG002","value":"26.9","lowerLimit":"16.8","upperLimit":"39.1"}]}]}]},{"type":"POST_HOC","title":"Extended Collection of Objective Response Rate (ORR) Per Investigator by Blood TMB (bTMB) (Blood TMB Cut-point = 21-mutations/MB)","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nBlood tumor mutational burden (bTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in serum.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","populationDescription":"All treated PD-L1 and bTMB evaluable Part 1 and Part 2 participants (Blood TMB Cut-point = 21-mutations/MB). Non-evaluable PD-L1 status means that PD-L1 status could not be determined, thus the Arm population did not meet this criteria. Not all participants were bTMB evaluable. To be analyzed participants had to be both PD-L1 evaluable and bTMB evaluable.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percent of Participants","timeFrame":"From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 67 months)","groups":[{"id":"OG000","title":"PART 1","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 2","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"131"}]}],"classes":[{"title":"bTMB High (Cut-point = 21-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"45"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"21.1","upperLimit":"78.9"},{"groupId":"OG002","value":"44.4","lowerLimit":"29.6","upperLimit":"60.0"}]}]},{"title":"bTMB Low (Cut-point = 21-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","lowerLimit":"9.8","upperLimit":"46.7"},{"groupId":"OG002","value":"23.3","lowerLimit":"14.8","upperLimit":"33.6"}]}]}]},{"type":"POST_HOC","title":"Extended Collection of Objective Response Rate (ORR) Per Investigator by Tissue TMB (Tissue TMB Cut-point = 10-mutations/MB)","description":"Objective response rate (ORR) is defined as the percent of treated participants with a best overall response of a complete response (CR) or partial response (PR) assessed by investigator per Response Evaluation Criteria In Solid Tumors (RECIST 1.1).\n\nPR is at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. CR is disappearance of all target lesions and a reduction in pathological lymph node (whether target or non-target) short axis to \\<10 mm.\n\nTissue tumor mutational burden (tTMB) is the total number of nonsynonymous somatic mutations produced by a tumor that are detected in tumor tissue samples.\n\nCR+PR, confidence interval based on the Clopper and Pearson method.","populationDescription":"All treated PD-L1 and bTMB evaluable Part 1 and Part 2 participants (Blood TMB Cut-point = 10-mutations/MB). Non-evaluable PD-L1 status means that PD-L1 status could not be determined, thus the Arm population did not meet this criteria. Not all participants were bTMB evaluable. To be analyzed participants had to be both PD-L1 evaluable and bTMB evaluable.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percent of Participants","timeFrame":"From first dose up to the date of objectively documented progression, or the date of initiation of palliative local therapy or the date of initiation of subsequent anticancer therapy (up to approximately 67 months)","groups":[{"id":"OG000","title":"PART 1","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG001","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first."},{"id":"OG002","title":"PART 2","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"101"}]}],"classes":[{"title":"tTMB High (Cut-point = 10-mutations)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","lowerLimit":"21.3","upperLimit":"73.4"},{"groupId":"OG002","value":"50.0","lowerLimit":"32.4","upperLimit":"67.6"}]}]},{"title":"tTMB Low (Cut-point = 10-mutations","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","lowerLimit":"5.7","upperLimit":"43.7"},{"groupId":"OG002","value":"19.4","lowerLimit":"10.8","upperLimit":"30.9"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Participants were assessed for all-cause mortality from their first dose to their study completion (up to approximately 67 months.) SAEs and Other AEs was assessed from first dose to 100 days post the last dose of study therapy (up to approximately an average of 8 months and a maximum of 29 months).","eventGroups":[{"id":"EG000","title":"PART 1: PD-L1+ Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first.","deathsNumAffected":27,"deathsNumAtRisk":31,"seriousNumAffected":24,"seriousNumAtRisk":31,"otherNumAffected":31,"otherNumAtRisk":31},{"id":"EG001","title":"PART 1: PD-L1- Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first.","deathsNumAffected":22,"deathsNumAtRisk":28,"seriousNumAffected":14,"seriousNumAtRisk":28,"otherNumAffected":27,"otherNumAtRisk":28},{"id":"EG002","title":"PART 1: Not Evaluable/Indeterminate PD-L1 Status","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first.","deathsNumAffected":1,"deathsNumAtRisk":1,"seriousNumAffected":0,"seriousNumAtRisk":1,"otherNumAffected":1,"otherNumAtRisk":1},{"id":"EG003","title":"PART 2: PD-L1 Status Independent","description":"Nivolumab + ipilimumab at a flat dose of nivolumab 240 mg as a 30-minute intravenous (IV) infusion every two weeks + ipilimumab 1 mg/kg as a 30-minute IV infusion every 6 weeks. Treatment would continue until disease progression, unacceptable toxicity, withdrawal of consent, the study ending, or a maximum treatment duration of 2 years, whichever occurred first","deathsNumAffected":134,"deathsNumAtRisk":170,"seriousNumAffected":113,"seriousNumAtRisk":170,"otherNumAffected":161,"otherNumAtRisk":170}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Nodal rhythm","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":4,"numAtRisk":170}]},{"term":"Thyroiditis","organSystem":"Endocrine disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Anal fissure","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Autoimmune pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":9,"numAtRisk":170}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Adverse drug reaction","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":4,"numAtRisk":170}]},{"term":"Inflammation","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Systemic inflammatory response syndrome","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Autoimmune hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Hepatitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Brain abscess","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Cytomegalovirus infection","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Empyema","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Encephalitis","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Klebsiella sepsis","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Oral fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":10,"numAtRisk":170}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Pneumonia pneumococcal","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Brachial plexus injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Depressed fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"General physical condition abnormal","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Troponin I increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":31},{"groupId":"EG001","numAffected":5,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":38,"numAtRisk":170}]},{"term":"Malignant pleural effusion","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Phaeochromocytoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Tumour necrosis","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Tumour ulceration","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Encephalitis autoimmune","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Metabolic encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Adnexa uteri mass","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":10,"numAtRisk":170}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":6,"numAtRisk":170}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":7,"numAtRisk":170}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":31},{"groupId":"EG001","numAffected":6,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":37,"numAtRisk":170}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":16,"numAtRisk":170}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31},{"groupId":"EG001","numAffected":5,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":15,"numAtRisk":170}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":8,"numAtRisk":170}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":7,"numAtRisk":170}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":4,"numAtRisk":170}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":31},{"groupId":"EG001","numAffected":9,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":25,"numAtRisk":170}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":31},{"groupId":"EG001","numAffected":12,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":65,"numAtRisk":170}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":12,"numAtRisk":170}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":4,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":7,"numAtRisk":170}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":14,"numAtRisk":170}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":4,"numAtRisk":170}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":31},{"groupId":"EG001","numAffected":11,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":48,"numAtRisk":170}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":8,"numAtRisk":170}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31},{"groupId":"EG001","numAffected":6,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":20,"numAtRisk":170}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":20,"numAtRisk":170}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":9,"numAtRisk":170}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":31},{"groupId":"EG001","numAffected":16,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":43,"numAtRisk":170}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":4,"numAtRisk":170}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":12,"numAtRisk":170}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":18,"numAtRisk":170}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":31},{"groupId":"EG001","numAffected":5,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":27,"numAtRisk":170}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":9,"numAtRisk":170}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":31},{"groupId":"EG001","numAffected":5,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":4,"numAtRisk":170}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":30,"numAtRisk":170}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":31},{"groupId":"EG001","numAffected":5,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":29,"numAtRisk":170}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":33,"numAtRisk":170}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":22,"numAtRisk":170}]},{"term":"Blood bicarbonate decreased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":22,"numAtRisk":170}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":31},{"groupId":"EG001","numAffected":7,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":28,"numAtRisk":170}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":4,"numAtRisk":170}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":20,"numAtRisk":170}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":31},{"groupId":"EG001","numAffected":9,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":38,"numAtRisk":170}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":6,"numAtRisk":170}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":19,"numAtRisk":170}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":12,"numAtRisk":170}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":31},{"groupId":"EG001","numAffected":4,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":12,"numAtRisk":170}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":8,"numAtRisk":170}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31},{"groupId":"EG001","numAffected":4,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":16,"numAtRisk":170}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":25,"numAtRisk":170}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":18,"numAtRisk":170}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":7,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":14,"numAtRisk":170}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":7,"numAtRisk":170}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":9,"numAtRisk":170}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":12,"numAtRisk":170}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":8,"numAtRisk":170}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31},{"groupId":"EG001","numAffected":5,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":25,"numAtRisk":170}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Peroneal nerve palsy","organSystem":"Nervous system disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":8,"numAtRisk":170}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":5,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":12,"numAtRisk":170}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":4,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":0,"numAtRisk":170}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31},{"groupId":"EG001","numAffected":10,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":45,"numAtRisk":170}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":31},{"groupId":"EG001","numAffected":12,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":45,"numAtRisk":170}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":8,"numAtRisk":170}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":3,"numAtRisk":170}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":10,"numAtRisk":170}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":17,"numAtRisk":170}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":1,"numAtRisk":170}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":1,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":3,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":15,"numAtRisk":170}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":31},{"groupId":"EG001","numAffected":0,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":5,"numAtRisk":170}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":31},{"groupId":"EG001","numAffected":10,"numAtRisk":28},{"groupId":"EG002","numAffected":1,"numAtRisk":1},{"groupId":"EG003","numAffected":43,"numAtRisk":170}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":31},{"groupId":"EG001","numAffected":8,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":42,"numAtRisk":170}]},{"term":"Rash maculo-papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":6,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":4,"numAtRisk":170}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":31},{"groupId":"EG001","numAffected":2,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":2,"numAtRisk":170}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":31},{"groupId":"EG001","numAffected":5,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":7,"numAtRisk":170}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":31},{"groupId":"EG001","numAffected":4,"numAtRisk":28},{"groupId":"EG002","numAffected":0,"numAtRisk":1},{"groupId":"EG003","numAffected":7,"numAtRisk":170}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"Bristol-Myers Squibb Study Director","organization":"Bristol-Myers Squibb","email":"Clinical.Trials@bms.com","phone":"Please email"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2019-12-18","uploadDate":"2023-02-02T14:17","filename":"Prot_SAP_000.pdf","size":27171942}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2023-03-03","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077594","term":"Nivolumab"},{"id":"D000074324","term":"Ipilimumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}